{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:50:01Z","timestamp":1782118201442,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02094-3","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:23:33Z","timestamp":1768667013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2706-6441","authenticated-orcid":false,"given":"Shahd","family":"Eghreib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9050-294X","authenticated-orcid":false,"given":"Seya","family":"Arafeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6682-9040","authenticated-orcid":false,"given":"Seham","family":"Natsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2752-2158","authenticated-orcid":false,"given":"Sara","family":"Rabieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2215-3481","authenticated-orcid":false,"given":"Mohammad","family":"Qabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-0449","authenticated-orcid":false,"given":"Beesan","family":"Maraqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"10159","key":"2094_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Lond Engl. 2018;392(10159):1789\u2013858.","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"2094_CR2","doi-asserted-by":"publisher","first-page":"e003558","DOI":"10.1136\/bmjopen-2013-003558","volume":"3","author":"NME Abu-Rmeileh","year":"2013","unstructured":"Abu-Rmeileh NME, Husseini A, Capewell S, O\u2019Flaherty M, MEDCHAMPS project. Preventing type 2 diabetes among palestinians: comparing five future policy scenarios. BMJ Open. 2013;3(12):e003558.","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"2094_CR3","doi-asserted-by":"publisher","first-page":"S783","DOI":"10.1016\/j.dsx.2017.05.017","volume":"11","author":"A Abu Al-Halaweh","year":"2017","unstructured":"Abu Al-Halaweh A, Davidovitch N, Almdal TP, Cowan A, Khatib S, Nasser-Eddin L, et al. Prevalence of type 2 diabetes mellitus complications among Palestinians with T2DM. Diabetes Metab Syndr. 2017;11(Suppl 2):S783\u20137.","journal-title":"Diabetes Metab Syndr"},{"key":"2094_CR4","unstructured":"Brijesh M, Saurav P. Comparative study of significance of serum Cystatin-C, serum creatinine and microalbuminuria Estimation in patients of early diabetic nephropathy. J Diabetes Metab. 2015;6(2):1\u20136."},{"key":"2094_CR5","unstructured":"Complications of diabetes mellitus: A review | Request PDF. ResearchGate [Internet]. 2025 Aug 7 [cited 2025 Oct 23]; Available from: https:\/\/www.researchgate.net\/publication\/332569443_Complications_of_diabetes_mellitus_A_review"},{"issue":"2","key":"2094_CR6","first-page":"216","volume":"32","author":"U Maggiore","year":"2017","unstructured":"Maggiore U, Budde K, Heemann U, Hilbrands L, Oberbauer R, Oniscu GC, et al. Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. Nephrol dial transplant off publ Eur dial transpl assoc -. Eur Ren Assoc. 2017;32(2):216\u201323.","journal-title":"Eur Ren Assoc"},{"issue":"2","key":"2094_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77\u201382.","journal-title":"Clin Diabetes"},{"issue":"4","key":"2094_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","volume":"13","author":"AN Long","year":"2011","unstructured":"Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens Greenwich. 2011;13(4):244\u201351.","journal-title":"J Clin Hypertens Greenwich"},{"issue":"3","key":"2094_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s13300-017-0256-5","volume":"8","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, et al. Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study. Diabetes Ther. 2017;8(3):555\u201371. https:\/\/doi.org\/10.1007\/s13300-017-0256-5. Epub 2017 Mar 30. PMID: 28361464; PMCID: PMC5446382.","journal-title":"Diabetes Ther"},{"issue":"12","key":"2094_CR10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2094_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","volume":"118","author":"JA Beckman","year":"2016","unstructured":"Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771\u201385.","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"2094_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"22","author":"NM Selby","year":"2020","unstructured":"Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3\u201315.","journal-title":"Diabetes Obes Metab"},{"issue":"1\u20133","key":"2094_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000441264","volume":"41","author":"H Sternlicht","year":"2016","unstructured":"Sternlicht H, Bakris GL. Management of hypertension in diabetic nephropathy: how low should we go? Blood Purif. 2016;41(1\u20133):139\u201343.","journal-title":"Blood Purif"},{"issue":"6","key":"2094_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211058856","volume":"18","author":"S Thipsawat","year":"2021","unstructured":"Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature. Diab Vasc Dis Res. 2021;18(6):14791641211058856.","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"2094_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000471765","volume":"3","author":"B Satirapoj","year":"2017","unstructured":"Satirapoj B. Sodium-glucose cotransporter 2 inhibitors with renoprotective effects. Kidney Dis. 2017;3(1):24\u201332. https:\/\/doi.org\/10.1159\/000471765. Epub 2017 Apr 8. PMID: 28785561; PMCID: PMC5527177.","journal-title":"Kidney Dis"},{"key":"2094_CR16","doi-asserted-by":"publisher","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;13(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744. Epub 2019 Apr 14. PMID: 30990260.","DOI":"10.1056\/NEJMoa1811744"},{"issue":"4","key":"2094_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262\u201374.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2094_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1517\/13543784.2014.892580","volume":"23","author":"R Hajhosseiny","year":"2014","unstructured":"Hajhosseiny R, Khavandi K, Jivraj N, Mashayekhi S, Goldsmith DJ, Malik RA. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs. 2014;23(4):511\u201322.","journal-title":"Expert Opin Investig Drugs"},{"key":"2094_CR19","unstructured":"Sciences, IJPPS) IJ of P and, DIABETIC NEPHROPATHY -GENESIS P, PREVENTION AND TREATMENT Review Article. Int J Pharm Pharm Sci [Internet]. 2014 Sept 1 [cited 2025 Oct 24]; Available from: https:\/\/www.academia.edu\/116462203\/DIABETIC_NEPHROPATHY_GENESIS_PREVENTION_AND_TREATMENT_Review_Article"},{"key":"2094_CR20","first-page":"212249","volume":"2013","author":"E Vivian","year":"2013","unstructured":"Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best? Drugs Context. 2013;2013:212249.","journal-title":"Drugs Context"},{"issue":"4","key":"2094_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.dsx.2015.02.008","volume":"9","author":"J Ahmad","year":"2015","unstructured":"Ahmad J. Management of diabetic nephropathy: recent progress and future perspective. Diabetes Metab Syndr. 2015;9(4):343\u201358.","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"2094_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/2042018814544153","volume":"5","author":"MC Thomas","year":"2014","unstructured":"Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(3):53\u201361. https:\/\/doi.org\/10.1177\/2042018814544153. PMID: 25126408; PMCID: PMC4132377.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2094_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2094_CR24","doi-asserted-by":"publisher","first-page":"e0217487","DOI":"10.1371\/journal.pone.0217487","volume":"14","author":"J Thornton Snider","year":"2019","unstructured":"Thornton Snider J, Sullivan J, van Eijndhoven E, Hansen MK, Bellosillo N, Neslusan C, et al. Lifetime benefits of early detection and treatment of diabetic kidney disease. PLoS One. 2019;14(5):e0217487. https:\/\/doi.org\/10.1371\/journal.pone.0217487. PMID: 31150444; PMCID: PMC6544227.","journal-title":"PLoS One"},{"issue":"7","key":"2094_CR25","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","volume":"37","author":"A Piperidou","year":"2019","unstructured":"Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou ME, et al. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(7):1334\u201343. https:\/\/doi.org\/10.1097\/HJH.0000000000002050. PMID: 31145707.","journal-title":"J Hypertens"},{"issue":"2","key":"2094_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2337\/diacare.10.2.191","volume":"10","author":"M Uusitupa","year":"1987","unstructured":"Uusitupa M, Siitonen O, Penttil\u00e4 I, Aro A, Py\u00f6r\u00e4l\u00e4 K. Proteinuria in newly diagnosed type II diabetic patients. Diabetes Care. 1987;10(2):191\u20134.","journal-title":"Diabetes Care"},{"key":"2094_CR27","unstructured":"2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes\u20142023 | Diabetes Care | American Diabetes Association [Internet]. [cited 2025 Oct 24]. Available from: https:\/\/diabetesjournals.org\/care\/article\/46\/Supplement_1\/S19\/148056\/2-Classification-and-Diagnosis-of-Diabetes"},{"key":"2094_CR28","unstructured":"Physical status. the use of and interpretation of anthropometry, report of a WHO expert committee [Internet]. [cited 2025 Oct 24]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9241208546"},{"key":"2094_CR29","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertens Dallas Tex 1979. 2018 June;71(6):1269\u2013324.","DOI":"10.1161\/HYP.0000000000000075"},{"issue":"Suppl 2","key":"2094_CR30","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165\u2013171.","journal-title":"Diabetes Care"},{"issue":"7","key":"2094_CR31","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2094_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","volume":"146","author":"K Umanath","year":"2022","unstructured":"Umanath K, Testani JM, Lewis JB. Dip in eGFR: stay the course with SGLT-2 inhibition. Circulation. 2022;146(6):463\u20135.","journal-title":"Circulation"},{"issue":"11","key":"2094_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/dia.2017.0134","volume":"19","author":"RE Brown","year":"2017","unstructured":"Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. Diabetes Technol Ther. 2017;19(11):685\u201391.","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"2094_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"2094_CR35","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.121.058103","volume":"145","author":"RHM Furtado","year":"2022","unstructured":"Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, et al. Efficacy and safety of Dapagliflozin in type 2 diabetes according to baseline blood pressure: observations from DECLARE-TIMI 58 trial. Circulation. 2022;145(21):1581\u201391.","journal-title":"Circulation"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02094-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:45:57Z","timestamp":1770835557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02094-3","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants, with clearly explained to them the purpose of the study, the potential benefits and risks of participation, the right to withdraw. No identifying information will be collected, and participants will be referred to as codes. They were also reassured that all data collected would remain confidential. Approval was secured from College of Medicine in Hebron University institutional review board (IRB). The consent mandated that any serious or unexpected events would be reported immediately to the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Human ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}